<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T07:50:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3824937" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:3824937</identifier>
        <datestamp>2013-11-21</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Ann Surg Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Ann Surg Oncol</journal-id>
              <journal-title-group>
                <journal-title>Annals of Surgical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1068-9265</issn>
              <issn pub-type="epub">1534-4681</issn>
              <publisher>
                <publisher-name>Springer US</publisher-name>
                <publisher-loc>Boston</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC3824937</article-id>
              <article-id pub-id-type="pmcid">PMC3824937</article-id>
              <article-id pub-id-type="pmc-uid">3824937</article-id>
              <article-id pub-id-type="pmid">23780381</article-id>
              <article-id pub-id-type="pmid">23780381</article-id>
              <article-id pub-id-type="publisher-id">3038</article-id>
              <article-id pub-id-type="doi">10.1245/s10434-013-3038-y</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Breast Oncology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mukhtar</surname>
                    <given-names>Rita A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yau</surname>
                    <given-names>Christina</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosen</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tandon</surname>
                    <given-names>Vickram J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>The I-SPY 1 TRIAL and ACRIN 6657 Investigators</collab>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hylton</surname>
                    <given-names>Nola</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Esserman</surname>
                    <given-names>Laura J.</given-names>
                  </name>
                  <address>
                    <email>laura.esserman@ucsfmedctr.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label>University of California, San Francisco, San Francisco, CA USA </aff>
                <aff id="Aff2"><label>2</label>University of Pennsylvania, Philadelphia, PA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>6</month>
                <year>2013</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>19</day>
                <month>6</month>
                <year>2013</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2013</year>
              </pub-date>
              <volume>20</volume>
              <issue>12</issue>
              <fpage>3823</fpage>
              <lpage>3830</lpage>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>4</month>
                  <year>2012</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2013</copyright-statement>
                <license license-type="OpenAccess" xlink:href="https://creativecommons.org/licenses/by/2.0/">
                  <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Purpose</title>
                  <p>This study was designed to determine (1) rates of clinically meaningful tumor reduction in breast tumor size following neoadjuvant chemotherapy (NAC), (2) which receptor subtypes and MRI phenotypes are associated with clinically meaningful tumor reduction, and (3) whether MRI phenotype impacts concordance between pathologic and MRI size.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>We analyzed data from the I-SPY TRIAL, a multicenter, prospective NAC trial. Reduction in tumor size from &gt;4 to ≤4 cm was considered clinically meaningful, as crossing this threshold was considered a reasonable cutoff for potential breast conservation therapy (BCT). MRI phenotypes were scored between one (well-defined) and five (diffuse) on pre-NAC MRIs.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Of 174 patients with tumors &gt;4 cm, 141 (81 %) had clinically meaningful tumor reduction. Response to therapy varied by MRI phenotype (<italic>p</italic> = 0.003), with well-defined phenotypes more likely than diffuse phenotypes to have clinically meaningful tumor shrinkage (91 vs. 72 %, <italic>p</italic> = 0.037). Her2+ and triple-negative (Tneg) tumors had the highest rate of clinically meaningful tumor reduction (<italic>p</italic> = 0.005). The concordance between tumor diameter on MRI and surgical pathology was highest for Her2+ and Tneg tumors, especially among tumors with solid imaging phenotypes (<italic>p</italic> = 0.004).</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p>NAC allows most patients with large breast tumors to have clinically meaningful tumor reduction, meaning response that would impact ability to undergo BCT. However, response varies by imaging and tumor subtypes. Concordance between tumor size on MRI and surgical pathology was higher in well-defined tumors, especially those with a Tneg subtype, and lower in HR+ diffuse tumors.</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (doi:10.1245/s10434-013-3038-y) contains supplementary material, which is available to authorized users.</p>
                </sec>
              </abstract>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Society of Surgical Oncology 2013</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>Neoadjuvant chemotherapy (NAC) is used increasingly for breast cancer treatment, with two main benefits: it offers the ability to monitor response to treatment, where pathologic complete response (pCR) is prognostic, and it can result in downstaging of tumor and breast conservation treatment (BCT) or eliminate the need for postmastectomy radiation in the setting of pCR.<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR6">6</xref> Many factors influence the choice of surgical procedure after NAC: patient preference, tumor appearance, hormone receptor (HR) and Her2 expression status, and treatment response.<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref> Whereas the post-NAC MRI often is used to determine whether BCT is possible, investigators note that the pre-NAC MRI influences surgeons’ recommendations, regardless of tumor appearance after NAC.<xref ref-type="bibr" rid="CR9">9</xref> Because clinicians and patients seek to avoid reexcision, it is important to understand the reliability of the postchemotherapy MRI.<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR13">13</xref>
</p>
            <p>Physical examination, ultrasound, and mammography have only moderate accuracy in predicting residual disease, whereas MRI longest diameter and volumetric measurements are the most accurate measures after chemotherapy.<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR17">17</xref> Despite this, both false positives and negatives remain. A better understanding of imaging reliability and which features predict successful BCT could affect surgical management.<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>
</p>
            <p>We previously identified that MRI phenotypes (solid and well-contained vs. diffuse and infiltrative) correspond with degree of response to NAC and predict the ability to achieve breast conservation.<xref ref-type="bibr" rid="CR20">20</xref> In this study, we investigated whether MRI phenotype and receptor subtype predicted rates of clinically meaningful tumor reduction in a larger cohort with imaging and molecular data. Surgeon comfort with attempting BCT varies and was not mandated; our primary endpoint therefore was crossing the threshold from &gt;4 cm to tumor size of ≤4 cm, a reasonable cutoff for potential BCT. We also investigated whether the correlation between tumor size on post-NAC MRI and surgical pathology differed by MRI phenotype and receptor subtype.</p>
            <sec id="Sec1" sec-type="materials|methods">
              <title>Methods</title>
              <sec id="Sec2">
                <title>Patients</title>
                <p>Patients received anthracycline-based chemotherapy, followed by a taxane regimen on the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657).<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref> Herceptin was used neoadjuvantly in Her2+ patients after 2005. This study was approved by the UCSF institutional review board.</p>
              </sec>
              <sec id="Sec3">
                <title>MRI Technique</title>
                <p>Contrast-enhanced MRI was performed on 1.5T MRI scanners using dedicated breast radiofrequency coils (details previously described).<xref ref-type="bibr" rid="CR21">21</xref> Unilateral images were acquired using 3D, fat-suppressed, T1-weighted spoiled gradient echo (SPGR) imaging with spatial resolution ≤1 mm/pixel in-plane and ≤2.5-mm slice thickness. Pre- and postgadolinium (0.1 mmol/kg) imaging was performed at prespecified temporal resolution to achieve imaging at ~2.5 and 7.5 min after contrast administration. Tumors were assigned one of five MRI phenotypes based on pre-NAC imaging: 1—well defined, unicentric mass; 2—well defined, multilobulated mass; 3—area enhancement with nodularity; 4—area enhancement without nodularity; 5—septal spreading (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Pre-NAC MRI phenotype was determined by a centrally trained breast radiologist at each study site.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Examples of each of the five MRI phenotypes: <bold>1</bold> well defined, unicentric mass; <bold>2</bold> well defined, multilobulated mass; <bold>3</bold> area enhancement with nodularity; <bold>4</bold> area enhancement without nodularity; <bold>5</bold> septal spreading</p></caption><graphic xlink:href="10434_2013_3038_Fig1_HTML" id="MO1"/></fig>
</p>
              </sec>
              <sec id="Sec4">
                <title>Determination of Tumor Marker Subtypes</title>
                <p>Core biopsies were obtained at each site before NAC, and immunohistochemical and genomic markers were performed as previously described.<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>
</p>
              </sec>
              <sec id="Sec5">
                <title>Postsurgical Pathology Analysis</title>
                <p>Seven study pathologists were trained on evaluation of gross and microscopic sections using a standardized tool: the residual cancer burden method.<xref ref-type="bibr" rid="CR22">22</xref> Training was done by Dr. Fraser Symmans, who reviewed the first five cases from each pathologist. An electronic tool was built to capture extent of disease. Pathology size was re-reviewed and longest diameter from this central re-review was used as the largest size.</p>
              </sec>
              <sec id="Sec6">
                <title>Definition of Clinically Meaningful Tumor Reduction</title>
                <p>Subjects were considered potentially eligible for BCT before receiving NAC if the tumor was ≤4 cm on both pre-NAC clinical examination and pre-NAC MRI. This cut point was chosen based on its use in the National Surgical Adjuvant Breast and Bowel Project B-06.<xref ref-type="bibr" rid="CR23">23</xref> Patients with tumors &gt;4 cm in size before NAC were considered to have a clinically meaningful tumor reduction if the tumor was ≤4 cm on surgical pathology. Discrepancy between post-NAC MRI and surgical pathology was defined as a difference in longest tumor diameter of ≥2 cm (cutoff based on internal consensus). Employment of stricter cutoffs (up to 1.5 cm) did not significantly alter our findings.</p>
              </sec>
              <sec id="Sec7">
                <title>Statistical Analysis</title>
                <p>As most variables were not normally distributed, median values and ranges are reported. The Kruskal–Wallis test was used to compare continuous variables, and contingency tables with the χ<sup>2</sup> test were used for categorical variables.<xref ref-type="bibr" rid="CR24">24</xref> MRI phenotypes were analyzed as five distinct categories, as well by dichotomization into well-defined versus diffuse categories. <italic>p</italic> values were two-sided, and <italic>p</italic> &lt; 0.05 based on contingency table χ<sup>2</sup> statistical test was considered significant.<xref ref-type="bibr" rid="CR25">25</xref>
</p>
              </sec>
            </sec>
            <sec id="Sec8" sec-type="results">
              <title>Results</title>
              <sec id="Sec9">
                <title>Clinical Characteristics</title>
                <p>Of the 221 subjects in the I-SPY TRIAL, 198 had data available for pre- and posttreatment MRIs, pretreatment clinical examinations, type of surgery, and surgical pathology; 193 had pre-NAC HR and Her2 status available.<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref> Of the 198 subjects in this study, 24 had tumors ≤4 cm on both pre-NAC clinical examination and pre-NAC MRI.</p>
              </sec>
              <sec id="Sec10">
                <title>Clinically Meaningful Tumor Reduction</title>
                <p>Of the 174 subjects with tumors &gt;4 cm on pre-NAC clinical examination and MRI, 141 (81 %) had a clinically meaningful tumor reduction after NAC based on a tumor size ≤4 cm on surgical pathology. Sixty-one of these 174 (35 %) subjects received BCT. Of the 141 subjects whose tumors shrank to ≤4 cm, 52 (37 %) received BCT, 2 (1.4 %) had attempted BCT but subsequently required mastectomy for positive margins, and 87 (62 %) underwent mastectomy. The most common reasons for not receiving BCT included multicentric disease (22 %) and patient choice (22 %; Supplementary Table 1).</p>
                <p>The response to NAC varied by MRI phenotype (<italic>p</italic> = 0.037). Patients with well-defined pre-NAC MRI phenotypes (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) had higher rates of clinically meaningful tumor reduction than those with diffuse phenotypes (92 vs. 72 %; Fig. <xref rid="Fig2" ref-type="fig">2</xref>a). The rates of BCT were higher in the well-defined phenotypes compared with the diffuse phenotypes (47 vs. 27 %, <italic>p</italic> = 0.023; Fig. <xref rid="Fig2" ref-type="fig">2</xref>a).
<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>a</bold> Bar plot showing percentage of patients who had clinically meaningful tumor reduction (<italic>blue</italic>) and who received BCT (<italic>yellow</italic>) after NAC by MRI phenotype; pink line represents the average rate of clinically meaningful tumor reduction (81 %). Subjects with well-defined MRI phenotypes (<italic>1</italic> and <italic>2</italic>) were more likely to have a clinically meaningful tumor reduction and receive BCT after NAC. <bold>b</bold> Bar plot showing same data by receptor subtype. Her2+ and Tneg tumors had a higher likelihood of having clinically meaningful tumor reduction after NAC compared to HR+/Her2− tumors; however, the actual rates of receiving BCT do not differ by subtype</p></caption><graphic xlink:href="10434_2013_3038_Fig2_HTML" id="MO2"/></fig>
</p>
                <p>The rate of clinically meaningful tumor reduction also varied by receptor subtype (<italic>p</italic> = 0.005). Her2+ and Tneg (HR−/Her2−) tumors had higher rates compared with the HR+/Her2− group (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). However, there was no significant difference in BCT rates (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). Analysis using a 3-cm cutoff for clinically meaningful tumor reduction yielded similar results.</p>
              </sec>
              <sec id="Sec11">
                <title>MRI/Pathology Concordance</title>
                <p>Pretreatment tumor size varied by MRI phenotype pattern (<italic>p</italic> = 0.002; Supplementary Table 2). In addition, tumor diameter on pre-NAC MRI differed significantly from tumor diameter by palpation (paired Wilcoxon rank-sum test, <italic>p</italic> = 0.01) and this difference varied by imaging phenotype (<italic>p</italic> = 0.003) with a median size difference of −0.4, −0.2, 0.9, 0.65, and 2 cm for phenotypes 1–5, respectively. Clinical diameter tended to be larger than MRI diameter in solid tumors. In diffuse phenotypes, the MRI size was larger than by clinical exam (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). One Tneg tumor was excluded from this analysis because the tumor took up the entire breast, so preoperative size was not recorded.
<fig id="Fig3"><label>Fig. 3</label><caption><p><italic>Vertical axis</italic> shows the difference in centimeters between tumor diameter on pre-NAC MRI and tumor diameter palpated on pre-NAC physical examination. <italic>Horizontal axis</italic> shows results by MRI phenotype. Overall, palpation underestimated tumor size in the diffuse tumors and slightly overestimated in solid tumors. Note that one Tneg case was left out of this analysis</p></caption><graphic xlink:href="10434_2013_3038_Fig3_HTML" id="MO3"/></fig>
</p>
                <p>The post-NAC MRI longest diameter measurements differed from diameter measured on surgical pathology (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Of the 198 subjects analyzed, 75 (38 %) had a discrepancy of ≥2 cm between size on imaging and pathology. Of the 75 discrepant cases, the tumor size on post-NAC MRI was greater than pathology in 52 cases (69 %) and smaller in 23 cases (31 %). There were 18 cases (9 %) in which pathology showed no tumor, but post-NAC MRI tumor size was ≥2 cm, and 7 cases (3.5 %) in which post-NAC MRI showed no tumor, but pathology showed ≥2 cm of tumor. MRI/pathology concordance varied by tumor subtype (<italic>p</italic> = 0.004), with size discrepancies present in half of all HR+/Her2− tumors but lower discrepancy rates in Her2+ and Tneg tumors. Underestimation of disease by &gt;2 cm was rare (4.3 %) in solid MRI tumor patterns. In cases where the post-NAC MRI underestimated the tumor size, all tumors were either diffuse and/or HR+/Her2− or Her2+, and none were Tneg. Within each marker subtype, diffuse tumors were more likely to have size discrepancies. Overall, diffuse HR+ Her2− tumors were most likely to have discrepancies between post-NAC MRI and surgical pathology (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Similar trends were observed among patients who received BCT (80/198 total patients analyzed), with the highest discrepancy rates in HR+ HER2− diffuse cases (31 vs. 19 % all others) and MRI underestimation of tumor size occurring only in diffuse and/or HR+ cases. Additionally, employing stricter cutoffs for discrepancy (up to 1.5 cm) did not alter these findings.
<fig id="Fig4"><label>Fig. 4</label><caption><p><italic>Vertical axis</italic> shows the difference in centimeters between post-NAC MRI longest diameter and tumor size on surgical pathology. Solid tumors had smaller size discrepancies than diffuse tumors. MRI underestimated path tumor size only in diffuse or HR+ tumors. For cases where MRI was accurate (&lt;2 cm difference), there were 72 solid and 51 diffuse cases. For cases were MRI overestimated path tumor size, there were 16 solid and 36 diffuse cases. MRI most often overestimated the size of diffuse tumors, except in the case of HR+/Her2− tumors. <italic>Circles</italic> represent MRI phenotypes <italic>1</italic> and <italic>2</italic>; <italic>Triangles</italic> are phenotypes <italic>3</italic>, <italic>4</italic>, and <italic>5</italic>
</p></caption><graphic xlink:href="10434_2013_3038_Fig4_HTML" id="MO4"/></fig>
</p>
              </sec>
              <sec id="Sec12">
                <title>MRI Phenotype and Tumor Subtype</title>
                <p>The most common patterns were MRI phenotypes 2 and 3 (Table <xref rid="Tab1" ref-type="table">1</xref>). There were significant differences in the receptor subtype distribution for well-defined versus diffuse MRI categories (<italic>p</italic> = 0.015 by χ<sup>2</sup> test). The Tneg (HR−/Her2−) group made up a larger proportion of the well-defined MRI phenotypes (35 %) than the diffuse phenotypes (15 %). The diffuse patterns had a higher proportion of HR+ cases (68 %) than the well-defined patterns (52 %; Fig. <xref rid="Fig5" ref-type="fig">5</xref>). However, all phenotypes were represented in each receptor subtype.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient and tumor characteristics: age, stage, histology, grade, chemotherapeutic regimens, HR/Her2 marker status, surgical treatment received, and MRI phenotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left">Total (<italic>n</italic> = 198)</th></tr><tr><th align="left">Number (%)</th></tr></thead><tbody><tr><td align="left">Median age (range)</td><td char="(" align="char">48.5 (26.7–68.8)</td></tr><tr><td align="left" colspan="2">Stage at presentation</td></tr><tr><td align="left"> I</td><td char="(" align="char">3 (1.5)</td></tr><tr><td align="left"> II</td><td char="(" align="char">93 (47)</td></tr><tr><td align="left"> III</td><td char="(" align="char">88 (44.4)</td></tr><tr><td align="left"> Inflammatory</td><td char="(" align="char">14 (7)</td></tr><tr><td align="left" colspan="2">Histology</td></tr><tr><td align="left"> Necrosis</td><td char="(" align="char">3 (1.5)</td></tr><tr><td align="left"> Ductal</td><td char="(" align="char">158 (80)</td></tr><tr><td align="left"> Lobular</td><td char="(" align="char">18 (9)</td></tr><tr><td align="left"> Mixed ductal-lobular</td><td char="(" align="char">7 (3.5)</td></tr><tr><td align="left"> Other/not available</td><td char="(" align="char">12 (6)</td></tr><tr><td align="left" colspan="2">Grade</td></tr><tr><td align="left"> 1</td><td char="(" align="char">14 (7)</td></tr><tr><td align="left"> 2</td><td char="(" align="char">90 (45.5)</td></tr><tr><td align="left"> 3</td><td char="(" align="char">90 (45.5)</td></tr><tr><td align="left"> Indeterminate</td><td char="(" align="char">4 (2)</td></tr><tr><td align="left" colspan="2">Chemotherapy regimen</td></tr><tr><td align="left"> Doxorubicin (A)/cyclophosphamide (C)</td><td char="(" align="char">9 (4.6)</td></tr><tr><td align="left"> Doxorubicin (A)/cyclophosphamide (C)/taxane</td><td char="(" align="char">171 (86.4)</td></tr><tr><td align="left"> Doxorubicin (A)/cyclophosphamide (C)/taxane/herceptin</td><td char="(" align="char">16 (8)</td></tr><tr><td align="left"> Doxorubicin (A)/cyclophosphamide (C)/taxane/other</td><td char="(" align="char">2 (1)</td></tr><tr><td align="left" colspan="2">Marker subtype</td></tr><tr><td align="left"> HR+/Her2−</td><td char="(" align="char">88 (44.4)</td></tr><tr><td align="left"> Her2+</td><td char="(" align="char">58 (29.7)</td></tr><tr><td align="left"> HR−/Her2−</td><td char="(" align="char">47 (23.7)</td></tr><tr><td align="left"> Unavailable</td><td char="(" align="char">5 (2.5)</td></tr><tr><td align="left" colspan="2">Surgical treatment</td></tr><tr><td align="left"> Lumpectomy</td><td char="(" align="char">80 (40.4)</td></tr><tr><td align="left"> Lumpectomy followed by mastectomy</td><td char="(" align="char">2 (1)</td></tr><tr><td align="left"> Mastectomy</td><td char="(" align="char">116 (59)</td></tr><tr><td align="left" colspan="2">MRI Phenotype</td></tr><tr><td align="left"> 1 well defined unicentric mass</td><td char="(" align="char">33 (16.7 %)</td></tr><tr><td align="left"> 2 well defined multilobulated mass</td><td char="(" align="char">59 (29.8 %)</td></tr><tr><td align="left"> 3 area enhancement with nodularity</td><td char="(" align="char">60 (30.3 %)</td></tr><tr><td align="left"> 4 area enhancement without nodularity</td><td char="(" align="char">28 (14.1 %)</td></tr><tr><td align="left"> 5 septal spreading</td><td char="(" align="char">18 (9.1 %)</td></tr><tr><td align="left" colspan="2">Potentially Eligible for BCT</td></tr><tr><td align="left" colspan="2"> Pre-NAC (palpation and MRI &lt;4 cm)</td></tr><tr><td align="left">  Yes</td><td char="(" align="char">24 (14 %)</td></tr><tr><td align="left">  No</td><td char="(" align="char">150 (86 %)</td></tr><tr><td align="left" colspan="2"> Post-NAC (pathology size &lt;4 cm)</td></tr><tr><td align="left">  Yes</td><td char="(" align="char">141 (81 %)</td></tr><tr><td align="left">  No</td><td char="(" align="char">33 (19 %)</td></tr></tbody></table></table-wrap>
<fig id="Fig5"><label>Fig. 5</label><caption><p>Whereas the relative proportions of tumor subtypes varied between the well-defined and diffuse MRI phenotypes, both groups contained all four receptor based subtypes</p></caption><graphic xlink:href="10434_2013_3038_Fig5_HTML" id="MO5"/></fig>
</p>
              </sec>
            </sec>
            <sec id="Sec13" sec-type="discussion">
              <title>Discussion</title>
              <p>Overall, the results in this prospective cohort of patients confirm our previous findings that tumor morphology, captured by MRI phenotype, and tumor subtype affect rates of achieving clinically meaningful tumor reduction after NAC.<xref ref-type="bibr" rid="CR26">26</xref> Patients with well-defined MRI phenotypes and those with Her2+ and Tneg tumors were more likely to have tumor shrinkage to ≤4 cm. We and others have found an improved correlation between post-NAC MRI and surgical pathology in tumors that are well-defined by imaging.<xref ref-type="bibr" rid="CR27">27</xref> Together, these findings suggest that MRI phenotype may be used in conjunction with tumor subtype to set appropriate expectations before undergoing NAC.</p>
              <p>MRI phenotype and tumor subtype likely reflect biological differences between tumors. Other phenotypic features are associated with different tumor subtypes. Basal-like breast tumors have distinct histologic and immunotypic properties, with characteristics, such as central scar, tumor necrosis, spindle cells, squamous metaplasia, high mitotic count, and high nuclear to cytoplasmic ratio.<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref> Most of these Tneg tumors have mass-like imaging patterns on MRI.<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref> Even on mammogram and ultrasound, breast cancer subtypes have imaging characteristics, with Tneg cancers more likely to have smooth margins.<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref>
</p>
              <p>MRI phenotype and marker status influenced the likelihood of size discrepancies between imaging and pathology. Similarly, Chen et al.<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR34">34</xref> found that MRI was less accurate in tumors that present as non-mass enhancement on MRI, and in another study suggest that MRI can be used more successfully to plan BCT in Her2+ patients. Others also have reported that post-NAC MRI appears to be less accurate in ER+ tumors and most accurate in Tneg or Her2+ tumors and that pre-NAC tumor size and response also impact accuracy.<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR37">37</xref> Although some have reported the highest accuracy of MRI for Her2− disease, not knowing HR status and differences in rates of traztuzumab use could potentially account for the disparate results.<xref ref-type="bibr" rid="CR38">38</xref> Benign proliferative processes can enhance on MRI and are difficult to differentiate from low-grade, ER+ DCIS lesions. False-positive MRI enhancement may reflect a spectrum of change within high-risk tissue, possibly explaining why it is difficult to distinguish residual tumor size in ER-positive patients, especially with diffuse disease.<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref>
</p>
              <p>We previously reported differences in response to NAC based on the five MRI phenotypes described. Patients with well-circumscribed masses had the greatest response to NAC.<xref ref-type="bibr" rid="CR20">20</xref> In the current study, the majority of patients (81 %) achieved shrinkage to tumor size ≤4 cm, whereas we previously found only 47 % achieved enough shrinkage to be potentially eligible for BCT.<xref ref-type="bibr" rid="CR26">26</xref> This was likely due to the addition of taxane, which doubles the pCR rate compared with doxorubicin alone.<xref ref-type="bibr" rid="CR41">41</xref> For tumor subtypes, adjusting for pre-NAC tumor size did not change our results. For MRI phenotype, we found that size and phenotype were associated, because diffuse tumors will necessarily occupy a larger space. The larger size of these diffuse tumors could influence the ability to reach the threshold of ≤4 cm, but separating the contribution of phenotype from size is not possible in this study. The tumor response to NAC also can affect MRI accuracy, with good correlation between MRI and pathology noted in tumors with extreme responses (either complete or none), and worse correlation among partial responders.<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref>
</p>
              <p>For the MRI phenotypes, the well-defined groups had higher BCT rates, but no difference was seen among tumor subtypes. Whereas patient choice was a factor in 22 % of cases that were potentially candidates for but did not receive BCT, other factors, such as physician recommendations, could play a role in surgical decisions. Knowing the accuracy of MRI could alter these recommendations. Interestingly, post-NAC MRI longest diameter showed a stronger association with surgical procedure than tumor size on surgical pathology or post-NAC mammographic longest diameter among the 175 patients assessed by all three methods (Wilcoxon rank-sum test, <italic>p</italic> = 0.001, 0.17, and 0.02 respectively). There was no significant difference in local recurrence or recurrence free survival between subjects who received BCT and those who received mastectomy.<xref ref-type="bibr" rid="CR44">44</xref>
</p>
              <p>More than one third of patients had a size discrepancy ≥2 cm between the post-NAC MRI and surgical pathology. Some have suggested that overestimation on MRI could be a result of taxane causing increased vascular permeability and gadolinium uptake, or related to an inflammatory infiltrate or necrosis.<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR45">45</xref> We found more discrepancies in the diffuse tumor phenotypes, which likely reflects increased difficulty in measuring tumor diameter. These discrepancies were particularly notable in the diffuse HR+/Her2− tumors and make it more difficult to set expectations based on post-NAC MRI in these tumor types. However, in the setting of HR− tumors of solid phenotypes, post-NAC imaging did not underestimate residual tumor size. When MRI showed a pCR, the surgical pathology was concordant.</p>
              <p>The strengths of this study include central assessment of HR/Her2 status and the consistent timing of MRIs. There were dedicated breast radiologists at each site who underwent centralized training to validate the MR phenotypes. Size assessment can be somewhat subjective, however, especially for diffuse tumors. Adding tumor volume measurements may help to decrease the chance of overestimating the tumor size compared to surgical pathology. Despite these limitations, however, the findings are consistent with those reported in the literature, with the additional finding that MRI size estimates are less likely to correspond well with pathology for HR+ diffuse tumors.</p>
              <p>These findings have clinical implications. Whereas the majority did not attain a pCR, most patients attained clinically meaningful tumor reduction. The MRI phenotype and tumor subtype can inform the discussion about the likelihood of achieving enough response to be potentially eligible for BCT. Whether this information would increase rates of receiving BCT is unknown, but increased understanding, particularly of the accuracy of post-NAC MRI, could impact recommendations and patient decisions.</p>
              <p>Overall, many more patients have clinically meaningful tumor reductions than have a pCR. Although the reasons for not receiving BCT are complex, there is likely room for improvement in offering BCT to more patients. We are currently developing an algorithm based on biologic and MRI features to help determine the chances of having a clinically meaningful tumor reduction and the likely accuracy of MR post-NAC to guide this decision-making process.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Electronic supplementary material</title>
              <sec id="Sec14">
                <p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10434_2013_3038_MOESM1_ESM.doc"><caption><p>Supplementary material 1 (DOC 99 kb)</p></caption></media></supplementary-material>
</p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>Nola Hylton, Laura J. Esserman—Co-last authors.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgment</title>
              <p>The research for Alliance (CALGB) 150007 and 150012 was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, M.D., Chair) and to the Alliance Statistical Center (Daniel J. Sargent, Ph.D., CA33601). Additional funding includes: National Cancer Institute Specialized Program of Research Excellence in Breast Cancer (CA58207), American College of Radiology Imaging Network (CA079778 &amp; CA080098), National Cancer Institute Center for Bioinformatics, The Breast Cancer Research Foundation, and Bruce and Martha Atwater. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Dr. Mukhtar received support from the California Breast Cancer Research Program (Post-doctoral fellowship 15FB-0108).</p>
            </ack>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Esserman</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)</article-title>
                  <source>Breast Cancer Res Treat.</source>
                  <year>2012</year>
                  <volume>132</volume>
                  <fpage>1049</fpage>
                  <lpage>1062</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10549-011-1895-2</pub-id>
                  <?supplied-pmid 22198468?>
                  <pub-id pub-id-type="pmid">22198468</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Esserman</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657</article-title>
                  <source>J Clin Oncol.</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <fpage>3242</fpage>
                  <lpage>3249</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2011.39.2779</pub-id>
                  <?supplied-pmid 22649152?>
                  <pub-id pub-id-type="pmid">22649152</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fisher</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of preoperative chemotherapy on the outcome of women with operable breast cancer</article-title>
                  <source>J Clin Oncol.</source>
                  <year>1998</year>
                  <volume>16</volume>
                  <issue>8</issue>
                  <fpage>2672</fpage>
                  <lpage>2685</lpage>
                  <?supplied-pmid 9704717?>
                  <pub-id pub-id-type="pmid">9704717</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wolmark</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18</article-title>
                  <source>J Natl Cancer Inst Monogr.</source>
                  <year>2001</year>
                  <volume>30</volume>
                  <fpage>96</fpage>
                  <lpage>102</lpage>
                  <pub-id pub-id-type="doi">10.1093/oxfordjournals.jncimonographs.a003469</pub-id>
                  <?supplied-pmid 11773300?>
                  <pub-id pub-id-type="pmid">11773300</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rastogi</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27</article-title>
                  <source>J Clin Oncol.</source>
                  <year>2008</year>
                  <volume>26</volume>
                  <issue>5</issue>
                  <fpage>778</fpage>
                  <lpage>785</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.15.0235</pub-id>
                  <?supplied-pmid 18258986?>
                  <pub-id pub-id-type="pmid">18258986</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hortobagyi</surname>
                      <given-names>GN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multimodal treatment of locoregionally advanced breast cancer</article-title>
                  <source>Cancer.</source>
                  <year>1983</year>
                  <volume>51</volume>
                  <issue>5</issue>
                  <fpage>763</fpage>
                  <lpage>768</lpage>
                  <pub-id pub-id-type="doi">10.1002/1097-0142(19830301)51:5&lt;763::AID-CNCR2820510502&gt;3.0.CO;2-C</pub-id>
                  <?supplied-pmid 6687377?>
                  <pub-id pub-id-type="pmid">6687377</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shenoy</surname>
                      <given-names>HG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer</article-title>
                  <source>Surg Oncol.</source>
                  <year>2009</year>
                  <volume>18</volume>
                  <issue>1</issue>
                  <fpage>65</fpage>
                  <lpage>71</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.suronc.2008.07.005</pub-id>
                  <?supplied-pmid 18760916?>
                  <pub-id pub-id-type="pmid">18760916</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Caldon</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Walters</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Reed</surname>
                      <given-names>MW</given-names>
                    </name>
                  </person-group>
                  <article-title>Changing trends in the decision-making preferences of women with early breast cancer</article-title>
                  <source>Br J Surg.</source>
                  <year>2008</year>
                  <volume>95</volume>
                  <issue>3</issue>
                  <fpage>312</fpage>
                  <lpage>318</lpage>
                  <pub-id pub-id-type="doi">10.1002/bjs.5964</pub-id>
                  <?supplied-pmid 17853508?>
                  <pub-id pub-id-type="pmid">17853508</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>JH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer</article-title>
                  <source>Ann Surg.</source>
                  <year>2009</year>
                  <volume>249</volume>
                  <issue>3</issue>
                  <fpage>448</fpage>
                  <lpage>454</lpage>
                  <pub-id pub-id-type="doi">10.1097/SLA.0b013e31819a6e01</pub-id>
                  <?supplied-pmid 19247033?>
                  <pub-id pub-id-type="pmid">19247033</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morrow</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Magnetic resonance imaging for screening, diagnosis, and eligibility for breast-conserving surgery: promises and pitfalls</article-title>
                  <source>Surg Oncol Clin N Am.</source>
                  <year>2010</year>
                  <volume>19</volume>
                  <issue>3</issue>
                  <fpage>475</fpage>
                  <lpage>492</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.soc.2010.03.003</pub-id>
                  <?supplied-pmid 20620922?>
                  <pub-id pub-id-type="pmid">20620922</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morrow</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Magnetic resonance imaging in the preoperative evaluation of breast cancer: primum non nocere</article-title>
                  <source>J Am Coll Surg.</source>
                  <year>2004</year>
                  <volume>198</volume>
                  <issue>2</issue>
                  <fpage>240</fpage>
                  <lpage>241</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2003.10.013</pub-id>
                  <?supplied-pmid 14759781?>
                  <pub-id pub-id-type="pmid">14759781</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Houssami</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer</article-title>
                  <source>J Clin Oncol.</source>
                  <year>2008</year>
                  <volume>26</volume>
                  <issue>19</issue>
                  <fpage>3248</fpage>
                  <lpage>3258</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.15.2108</pub-id>
                  <?supplied-pmid 18474876?>
                  <pub-id pub-id-type="pmid">18474876</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kwong</surname>
                      <given-names>MS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer</article-title>
                  <source>Cancer J.</source>
                  <year>2006</year>
                  <volume>12</volume>
                  <issue>3</issue>
                  <fpage>212</fpage>
                  <lpage>221</lpage>
                  <pub-id pub-id-type="doi">10.1097/00130404-200605000-00010</pub-id>
                  <?supplied-pmid 16803680?>
                  <pub-id pub-id-type="pmid">16803680</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chagpar</surname>
                      <given-names>AB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy</article-title>
                  <source>Ann Surg.</source>
                  <year>2006</year>
                  <volume>243</volume>
                  <issue>2</issue>
                  <fpage>257</fpage>
                  <lpage>264</lpage>
                  <pub-id pub-id-type="doi">10.1097/01.sla.0000197714.14318.6f</pub-id>
                  <?supplied-pmid 16432360?>
                  <pub-id pub-id-type="pmid">16432360</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bhattacharyya</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer</article-title>
                  <source>Br J Cancer.</source>
                  <year>2008</year>
                  <volume>98</volume>
                  <issue>2</issue>
                  <fpage>289</fpage>
                  <lpage>293</lpage>
                  <pub-id pub-id-type="doi">10.1038/sj.bjc.6604171</pub-id>
                  <?supplied-pmid 18219287?>
                  <pub-id pub-id-type="pmid">18219287</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McLaughlin</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hylton</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>MRI in breast cancer therapy monitoring</article-title>
                  <source>NMR Biomed.</source>
                  <year>2011</year>
                  <volume>24</volume>
                  <issue>6</issue>
                  <fpage>712</fpage>
                  <lpage>720</lpage>
                  <?supplied-pmid 21692116?>
                  <pub-id pub-id-type="pmid">21692116</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lorenzon</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Assessment of breast cancer response to neoadjuvant chemotherapy: is volumetric MRI a reliable tool?</article-title>
                  <source>Eur J Radiol.</source>
                  <year>2009</year>
                  <volume>71</volume>
                  <issue>1</issue>
                  <fpage>82</fpage>
                  <lpage>88</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejrad.2008.03.021</pub-id>
                  <?supplied-pmid 18472240?>
                  <pub-id pub-id-type="pmid">18472240</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stucky</surname>
                      <given-names>CC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Does magnetic resonance imaging accurately predict residual disease in breast cancer?</article-title>
                  <source>Am J Surg.</source>
                  <year>2009</year>
                  <volume>198</volume>
                  <issue>4</issue>
                  <fpage>547</fpage>
                  <lpage>552</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.amjsurg.2009.04.008</pub-id>
                  <?supplied-pmid 19800466?>
                  <pub-id pub-id-type="pmid">19800466</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MRI before reexcision surgery in patients with breast cancer</article-title>
                  <source>AJR Am J Roentgenol.</source>
                  <year>2004</year>
                  <volume>182</volume>
                  <issue>2</issue>
                  <fpage>473</fpage>
                  <lpage>480</lpage>
                  <pub-id pub-id-type="doi">10.2214/ajr.182.2.1820473</pub-id>
                  <?supplied-pmid 14736685?>
                  <pub-id pub-id-type="pmid">14736685</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Esserman</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer</article-title>
                  <source>Ann Surg Oncol.</source>
                  <year>2001</year>
                  <volume>8</volume>
                  <issue>6</issue>
                  <fpage>549</fpage>
                  <lpage>559</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10434-001-0549-8</pub-id>
                  <?supplied-pmid 11456056?>
                  <pub-id pub-id-type="pmid">11456056</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hylton</surname>
                      <given-names>NM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy results from ACRIN 6657/I-SPY TRIAL</article-title>
                  <source>Radiology.</source>
                  <year>2012</year>
                  <volume>263</volume>
                  <issue>3</issue>
                  <fpage>663</fpage>
                  <lpage>672</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.12110748</pub-id>
                  <?supplied-pmid 22623692?>
                  <pub-id pub-id-type="pmid">22623692</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Symmans</surname>
                      <given-names>WF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy</article-title>
                  <source>J Clin Oncol.</source>
                  <year>2007</year>
                  <volume>25</volume>
                  <issue>28</issue>
                  <fpage>4414</fpage>
                  <lpage>4422</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.10.6823</pub-id>
                  <?supplied-pmid 17785706?>
                  <pub-id pub-id-type="pmid">17785706</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fisher</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer</article-title>
                  <source>N Engl J Med.</source>
                  <year>2002</year>
                  <volume>347</volume>
                  <issue>16</issue>
                  <fpage>1233</fpage>
                  <lpage>1241</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa022152</pub-id>
                  <?supplied-pmid 12393820?>
                  <pub-id pub-id-type="pmid">12393820</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kruskal</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Wallis</surname>
                      <given-names>WA</given-names>
                    </name>
                  </person-group>
                  <article-title>Citation classic: use of ranks in one-criterion variance analysis</article-title>
                  <source>Curr Contents Arts Humanit</source>
                  <year>1987</year>
                  <volume>40</volume>
                  <fpage>20</fpage>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pearson</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <source>On the theory of contingency and its relation to association and normal correlation</source>
                  <year>1904</year>
                  <publisher-loc>London</publisher-loc>
                  <publisher-name>Dulau and Co</publisher-name>
                  <fpage>35</fpage>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <mixed-citation publication-type="other">Gomez R, et al. Preliminary results from I-SPY trial: tumor patterns on pre-treatment MRI predict breast conservation therapy eligibility. In: San Antonio Breast Cancer Symposium 2007: San Antonio, TX.</mixed-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McGuire</surname>
                      <given-names>KP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?</article-title>
                  <source>Ann Surg Oncol.</source>
                  <year>2011</year>
                  <volume>18</volume>
                  <issue>11</issue>
                  <fpage>3149</fpage>
                  <lpage>3154</lpage>
                  <pub-id pub-id-type="doi">10.1245/s10434-011-1912-z</pub-id>
                  <?supplied-pmid 21947592?>
                  <pub-id pub-id-type="pmid">21947592</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Livasy</surname>
                      <given-names>CA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma</article-title>
                  <source>Mod Pathol.</source>
                  <year>2006</year>
                  <volume>19</volume>
                  <issue>2</issue>
                  <fpage>264</fpage>
                  <lpage>271</lpage>
                  <pub-id pub-id-type="doi">10.1038/modpathol.3800528</pub-id>
                  <?supplied-pmid 16341146?>
                  <pub-id pub-id-type="pmid">16341146</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fulford</surname>
                      <given-names>LG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast</article-title>
                  <source>Histopathology.</source>
                  <year>2006</year>
                  <volume>49</volume>
                  <issue>1</issue>
                  <fpage>22</fpage>
                  <lpage>34</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2559.2006.02453.x</pub-id>
                  <?supplied-pmid 16842243?>
                  <pub-id pub-id-type="pmid">16842243</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>JH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Triple-negative breast cancer: MRI features in 29 patients</article-title>
                  <source>Ann Oncol.</source>
                  <year>2007</year>
                  <volume>18</volume>
                  <issue>12</issue>
                  <fpage>2042</fpage>
                  <lpage>2043</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdm504</pub-id>
                  <?supplied-pmid 18029970?>
                  <pub-id pub-id-type="pmid">18029970</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Uematsu</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Kasami</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Yuen</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Triple-negative breast cancer: correlation between MR imaging and pathologic findings</article-title>
                  <source>Radiology.</source>
                  <year>2009</year>
                  <volume>250</volume>
                  <issue>3</issue>
                  <fpage>638</fpage>
                  <lpage>647</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.2503081054</pub-id>
                  <?supplied-pmid 19244039?>
                  <pub-id pub-id-type="pmid">19244039</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression</article-title>
                  <source>Radiology.</source>
                  <year>2008</year>
                  <volume>246</volume>
                  <issue>2</issue>
                  <fpage>367</fpage>
                  <lpage>375</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.2462070169</pub-id>
                  <?supplied-pmid 18180338?>
                  <pub-id pub-id-type="pmid">18180338</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The mammographic correlations with basal-like phenotype of invasive breast cancer</article-title>
                  <source>Acad Radiol.</source>
                  <year>2010</year>
                  <volume>17</volume>
                  <issue>3</issue>
                  <fpage>333</fpage>
                  <lpage>339</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.acra.2009.10.011</pub-id>
                  <?supplied-pmid 19962918?>
                  <pub-id pub-id-type="pmid">19962918</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>JH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy</article-title>
                  <source>Cancer.</source>
                  <year>2008</year>
                  <volume>112</volume>
                  <issue>1</issue>
                  <fpage>17</fpage>
                  <lpage>26</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.23130</pub-id>
                  <?supplied-pmid 18000804?>
                  <pub-id pub-id-type="pmid">18000804</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Straver</surname>
                      <given-names>ME</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy</article-title>
                  <source>Ann Surg.</source>
                  <year>2010</year>
                  <volume>251</volume>
                  <issue>4</issue>
                  <fpage>701</fpage>
                  <lpage>707</lpage>
                  <pub-id pub-id-type="doi">10.1097/SLA.0b013e3181c5dda3</pub-id>
                  <?supplied-pmid 20224378?>
                  <pub-id pub-id-type="pmid">20224378</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Loo</surname>
                      <given-names>CE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype</article-title>
                  <source>J Clin Oncol.</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>6</issue>
                  <fpage>660</fpage>
                  <lpage>666</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.31.1258</pub-id>
                  <?supplied-pmid 21220595?>
                  <pub-id pub-id-type="pmid">21220595</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <mixed-citation publication-type="other">Nakahara H, et al. MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes. <italic>Breast Cancer</italic>. 2010;18(3):152–60.</mixed-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moon</surname>
                      <given-names>HG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment</article-title>
                  <source>Ann Oncol.</source>
                  <year>2009</year>
                  <volume>20</volume>
                  <issue>4</issue>
                  <fpage>636</fpage>
                  <lpage>641</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdn683</pub-id>
                  <?supplied-pmid 19179551?>
                  <pub-id pub-id-type="pmid">19179551</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Esserman</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Magnetic resonance imaging captures the biology of ductal carcinoma in situ</article-title>
                  <source>J Clin Oncol.</source>
                  <year>2006</year>
                  <volume>24</volume>
                  <issue>28</issue>
                  <fpage>4603</fpage>
                  <lpage>4610</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2005.04.5518</pub-id>
                  <?supplied-pmid 17008702?>
                  <pub-id pub-id-type="pmid">17008702</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kumar</surname>
                      <given-names>AS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ</article-title>
                  <source>Am J Surg.</source>
                  <year>2006</year>
                  <volume>192</volume>
                  <issue>4</issue>
                  <fpage>520</fpage>
                  <lpage>524</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.amjsurg.2006.07.003</pub-id>
                  <?supplied-pmid 16978965?>
                  <pub-id pub-id-type="pmid">16978965</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mamounas</surname>
                      <given-names>EP</given-names>
                    </name>
                  </person-group>
                  <article-title>NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel</article-title>
                  <source>Oncology (Williston Park).</source>
                  <year>1997</year>
                  <volume>11</volume>
                  <issue>6 Suppl 6</issue>
                  <fpage>37</fpage>
                  <lpage>40</lpage>
                  <?supplied-pmid 9213327?>
                  <pub-id pub-id-type="pmid">9213327</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fangberget</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging</article-title>
                  <source>Eur Radiol.</source>
                  <year>2011</year>
                  <volume>21</volume>
                  <issue>6</issue>
                  <fpage>1188</fpage>
                  <lpage>1199</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00330-010-2020-3</pub-id>
                  <?supplied-pmid 21127880?>
                  <pub-id pub-id-type="pmid">21127880</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wasser</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy</article-title>
                  <source>Eur Radiol.</source>
                  <year>2003</year>
                  <volume>13</volume>
                  <issue>6</issue>
                  <fpage>1213</fpage>
                  <lpage>1223</lpage>
                  <?supplied-pmid 12764635?>
                  <pub-id pub-id-type="pmid">12764635</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <mixed-citation publication-type="other">Alvarado M, et al. Predictors of local recurrence in high-risk patients undergoing neoadjuvant chemotherapy in the ISPY trial. In: San Antonio Breast Cancer Symposium. 2010. San Antonio, TX.</mixed-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>HJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI</article-title>
                  <source>Acta Oncol.</source>
                  <year>2007</year>
                  <volume>46</volume>
                  <issue>7</issue>
                  <fpage>996</fpage>
                  <lpage>1003</lpage>
                  <pub-id pub-id-type="doi">10.1080/02841860701373587</pub-id>
                  <?supplied-pmid 17851879?>
                  <pub-id pub-id-type="pmid">17851879</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
